GSK Sees Cervarix Cross-Protection, Age Range As Key Points Of Differentiation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline expects to highlight a broad age range and cross-protection against multiple viral strains to differentiate its human papilloma virus vaccine Cervarix from Merck’s competing vaccine Gardasil.
You may also be interested in...
GSK Wagers On Cervarix In Head-To-Head Trial Against Merck’s Gardasil
GlaxoSmithKline raised the stakes behind its anticipated launch of the investigational cervical cancer vaccine Cervarix Jan. 18, announcing the initiation of the first head-to-head trial comparing it to Merck's Gardasil. The study will evaluate differences between the two vaccines in inducing strong and sustained immune responses to the human papilloma virus in women
Merck Gardasil BLA a priority?
Merck is requesting a priority review for its human papillomavirus vaccine Gardasil (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant), submitted Dec. 1. If granted a priority review, a June 1, 2006 approval would allow Merck to launch the vaccine before the 2006 back-to-school immunization season. GlaxoSmithKline continues development of its HPV vaccine Cervarix, which it claims offers viral protection against multiple viral strains and in a wider age group than Gardasil (Pharmaceutical Approvals Monthly July 2005, p. 4). GSK said it plans to submit Cervarix in 2006...
Merck Gardasil BLA a priority?
Merck is requesting a priority review for its human papillomavirus vaccine Gardasil (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant), submitted Dec. 1. If granted a priority review, a June 1, 2006 approval would allow Merck to launch the vaccine before the 2006 back-to-school immunization season. GlaxoSmithKline continues development of its HPV vaccine Cervarix, which it claims offers viral protection against multiple viral strains and in a wider age group than Gardasil (Pharmaceutical Approvals Monthly July 2005, p. 4). GSK said it plans to submit Cervarix in 2006...